Are Physiologically Based Pharmacokinetic Models Reporting the Right Cmax? Central Venous Versus Peripheral Sampling Site
Journal Title: The AAPS Journal - Year 2015, Vol 17, Issue 5
Abstract
The online version of this article (doi:10.1208/s12248-015-9796-7) contains supplementary material, which is available to authorized users.
Authors and Affiliations
Helen Musther, Katherine L. Gill, Manoranjenni Chetty, Amin Rostami-Hodjegan, Malcolm Rowland, Masoud Jamei
Keywords
Related Articles
- EP ID EP681008
- DOI 10.1208/s12248-015-9796-7
- Views 51
- Downloads 0
Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology
Sodium–glucose co-transporter-2 (SGLT2) inhibitors are an emerging class of agents for use in the treatment of type 2 diabetes mellitus (T2DM). Inhibition of SGLT2 leads to improved glycemic control through incre...
Simultaneous Analysis of Multiple Monoclonal Antibody Biotherapeutics by LC-MS/MS Method in Rat Plasma Following Cassette-Dosing
The online version of this article (doi:10.1208/s12248-012-9435-5) contains supplementary material, which is available to authorized users.
Diurnal Variation in P-glycoprotein-Mediated Transport and Cerebrospinal Fluid Turnover in the Brain
The online version of this article (doi:10.1208/s12248-014-9625-4) contains supplementary material, which is available to authorized users.
Regulator of G-protein Signaling (RGS)1 and RGS10 Proteins as Potential Drug Targets for Neuroinflammatory and Neurodegenerative Diseases
Regulator of G-protein signaling (RGS) proteins were originally identified as negative regulators of G-protein-coupled receptor (GPCR) signaling via their GTPase-accelerating protein (GAP) activity. All RGS proteins cont...
Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans
Repifermin (truncated, recombinant human keratinocyte growth factor-2, KGF-2) was evaluated in cynomolgus monkeys and healthy humans during a phase 1 trial. Monkeys received vehicle or repifermin at 20, 75, or 200 ...